Acute Lymphoblastic Leukaemia Recurrent Recruiting Phase 2 Trials for Cytarabine (DB00987)

Also known as: Acute lymphoblastic leukemia recurrent / Recurrent Acute lymphoblastic leukemia / Acute, recurrent Lymphoblastic Leukaemia / Relapsed ALL / Acute, recurrent Lymphoblastic Leukemia / Acute, relapsed Lymphoblastic Leukemia / Relapsed Acute Lymphoblastic Leukemia / Acute lymphocytic leukemia recurrent / Acute lymphocytic leukaemia recurrent

IndicationStatusPhase
DBCOND0083559 (Acute Lymphoblastic Leukaemia Recurrent)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03263572Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic LeukemiaTreatment
NCT03147612Low-Intensity Chemotherapy and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic LeukemiaTreatment
NCT03575325Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic LeukemiaTreatment